Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov. Updates regarding government operating status and resumption of normal operations can be found at OPM.gov.
| Official Gene Symbol | Other Aliases |
|---|---|
| RAF1 | RAF |
| Sequence Length (AA) | Molecular Weight (Da) |
|---|---|
| 648 | 73052 |
| Protein Name |
|---|
| RAF proto-oncogene serine/threonine-protein kinase |
| Sources | |
|---|---|
|
UniProt PhosphoSitePlus ® GeneCards |
Human Protein Atlas |
| 10 | 20 | 30 | 40 | 50 |
| MEHIQGAWKT | ISNGFGFKDA | VFDGSSCISP | TIVQQFGYQR | RASDDGKLTD |
| 60 | 70 | 80 | 90 | 100 |
| PSKTSNTIRV | FLPNKQRTVV | NVRNGMSLHD | CLMKALKVRG | LQPECCAVFR |
| 110 | 120 | 130 | 140 | 150 |
| LLHEHKGKKA | RLDWNTDAAS | LIGEELQVDF | LDHVPLTTHN | FARKTFLKLA |
| 160 | 170 | 180 | 190 | 200 |
| FCDICQKFLL | NGFRCQTCGY | KFHEHCSTKV | PTMCVDWSNI | RQLLLFPNST |
| 210 | 220 | 230 | 240 | 250 |
| IGDSGVPALP | SLTMRRMRES | VSRMPVSSQH | RYSTPHAFTF | NTSSPSSEGS |
| 260 | 270 | 280 | 290 | 300 |
| LSQRQRSTST | PNVHMVSTTL | PVDSRMIEDA | IRSHSESASP | SALSSSPNNL |
| 310 | 320 | 330 | 340 | 350 |
| SPTGWSQPKT | PVPAQRERAP | VSGTQEKNKI | RPRGQRDSSY | YWEIEASEVM |
| 360 | 370 | 380 | 390 | 400 |
| LSTRIGSGSF | GTVYKGKWHG | DVAVKILKVV | DPTPEQFQAF | RNEVAVLRKT |
| 410 | 420 | 430 | 440 | 450 |
| RHVNILLFMG | YMTKDNLAIV | TQWCEGSSLY | KHLHVQETKF | QMFQLIDIAR |
| 460 | 470 | 480 | 490 | 500 |
| QTAQGMDYLH | AKNIIHRDMK | SNNIFLHEGL | TVKIGDFGLA | TVKSRWSGSQ |
| 510 | 520 | 530 | 540 | 550 |
| QVEQPTGSVL | WMAPEVIRMQ | DNNPFSFQSD | VYSYGIVLYE | LMTGELPYSH |
| 560 | 570 | 580 | 590 | 600 |
| INNRDQIIFM | VGRGYASPDL | SKLYKNCPKA | MKRLVADCVK | KVKEERPLFP |
| 610 | 620 | 630 | 640 | 648 |
| QILSSIELLQ | HSLPKINRSA | SEPSLHRAAH | TEDINACTLT | TSPRLPVF |
Data source: UniProt
Uniprot Database Entry PhosphoSitePlus ®
loading
Data source: Panorama
View Details (opens in a new window)
Abelin, et al. Mol Cell Proteomics. 2016 May;15(5):1622-41. doi: 10.1074/mcp.M116.058354. Epub 2016 Feb 24. PMID:26912667
Data source: Panorama
Broad Institute-Biologist curated set of targets across a number of important cancer pathways
Data source: Panorama
Data source: Panorama
Retrieving Data
Data source: Panorama
| Average intra-assay CV (within day CV) |
Average inter-assay CV (between day CV) |
Total CV |
n= | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Fragment ion / Transition | Low | Med | High | Low | Med | High | Low | Med | High | Low | Med | High |
| y6 (1+) | 11.1 | 9.2 | 10.1 | 9.8 | 10.1 | 10.8 | 14.8 | 13.7 | 14.8 | 15 | 15 | 15 |
| y5 (1+) | 13.3 | 8.6 | 12 | 12.4 | 9.1 | 16.1 | 18.2 | 12.5 | 20.1 | 15 | 15 | 15 |
| b4-98 (1+) | 12.9 | 10.4 | 12.8 | 14.4 | 13.2 | 15 | 19.3 | 16.8 | 19.7 | 15 | 15 | 15 |
| sum | 6.6 | 6.1 | 8.2 | 7.6 | 6.2 | 11 | 10.1 | 8.7 | 13.7 | 15 | 15 | 15 |
Data source: Panorama
View Details (opens in a new window)
Abelin, et al. Mol Cell Proteomics. 2016 May;15(5):1622-41. doi: 10.1074/mcp.M116.058354. Epub 2016 Feb 24. PMID:26912667
Data source: Panorama
Broad Institute-Biologist curated set of targets across a number of important cancer pathways
Data source: Panorama
Data source: Panorama
Retrieving Data
Data source: Panorama
| Average intra-assay CV (within day CV) |
Average inter-assay CV (between day CV) |
Total CV |
n= | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Fragment ion / Transition | Low | Med | High | Low | Med | High | Low | Med | High | Low | Med | High |
| y6 (1+) | 17.2 | 13.1 | 7.7 | 13.8 | 18.3 | 13.1 | 22.1 | 22.5 | 15.2 | 15 | 15 | 15 |
| y5 (1+) | 5 | 5.2 | 5.6 | 8.1 | 6.8 | 10.5 | 9.5 | 8.6 | 11.9 | 15 | 15 | 15 |
| b4-98 (1+) | 22.4 | 14.1 | 12.1 | 26.4 | 20.4 | 17.9 | 34.6 | 24.8 | 21.6 | 15 | 15 | 15 |
| sum | 6.8 | 3.2 | 5.6 | 10.1 | 5.4 | 10.5 | 12.2 | 6.3 | 11.9 | 15 | 15 | 15 |
Data source: Panorama
View Details (opens in a new window)
Targeted mass spectrometry-based assays enable multiplex quantification of receptor tyrosine kinase, MAP Kinase, and AKT signaling. Whiteaker JR, Sharma K, Hoffman MA, Kuhn E, Zhao L, Cocco AR, Schoenherr RM, Kennedy JJ, Voytovich U, Lin C, Fang B, Bowers K, Whiteley G, Colantonio S, Bocik W, Roberts R, Hiltke T, Boja E, Rodriguez H, McCormick F, Holderfield M, Carr SA, Koomen JM, Paulovich AG. Cell Reports Methods doi: 10.1016/j.crmeth.2021.100015.
Data source: Panorama
Broad Institute-Biologist curated set of targets across a number of important cancer pathways
Data source: Panorama
Data source: Panorama
Retrieving Data
Data source: Panorama
| Average intra-assay CV (within day CV) |
Average inter-assay CV (between day CV) |
Total CV |
n= | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Fragment ion / Transition | Low | Med | High | Low | Med | High | Low | Med | High | Low | Med | High |
| y6 (1+) | 26.3 | 14.3 | 8.5 | 24.9 | 30.6 | 16.4 | 36.2 | 33.8 | 18.5 | 15 | 15 | 15 |
| y7 (1+) | 32.3 | 17.6 | 9 | 35.2 | 32.8 | 13.4 | 47.8 | 37.2 | 16.1 | 15 | 15 | 15 |
| y8 (1+) | 20.1 | 12.7 | 6.3 | 29.7 | 30.2 | 14.3 | 35.9 | 32.8 | 15.6 | 15 | 15 | 15 |
| sum | 19.1 | 12.7 | 6.5 | 26.9 | 30.2 | 14.3 | 33 | 32.8 | 15.7 | 15 | 15 | 15 |
Data source: Panorama
View Details (opens in a new window)
Targeted mass spectrometry-based assays enable multiplex quantification of receptor tyrosine kinase, MAP Kinase, and AKT signaling. Whiteaker JR, Sharma K, Hoffman MA, Kuhn E, Zhao L, Cocco AR, Schoenherr RM, Kennedy JJ, Voytovich U, Lin C, Fang B, Bowers K, Whiteley G, Colantonio S, Bocik W, Roberts R, Hiltke T, Boja E, Rodriguez H, McCormick F, Holderfield M, Carr SA, Koomen JM, Paulovich AG. Cell Reports Methods doi: 10.1016/j.crmeth.2021.100015.
Data source: Panorama
Broad Institute-Biologist curated set of targets across a number of important cancer pathways
Data source: Panorama
Data source: Panorama
Retrieving Data
Data source: Panorama
| Average intra-assay CV (within day CV) |
Average inter-assay CV (between day CV) |
Total CV |
n= | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Fragment ion / Transition | Low | Med | High | Low | Med | High | Low | Med | High | Low | Med | High |
| y5 (1+) | 21.1 | 10.6 | 7.5 | 24.6 | 26 | 16.3 | 32.4 | 28.1 | 17.9 | 15 | 15 | 15 |
| y6 (1+) | 18.6 | 11.7 | 6.8 | 24.7 | 29.5 | 17.7 | 30.9 | 31.7 | 19 | 15 | 15 | 15 |
| y7 (1+) | 19.3 | 12.2 | 5.5 | 24.8 | 29.5 | 16.1 | 31.4 | 31.9 | 17 | 15 | 15 | 15 |
| sum | 18.5 | 11.6 | 6.2 | 24.1 | 28.7 | 16.5 | 30.4 | 31 | 17.6 | 15 | 15 | 15 |
Data source: Panorama
View Details (opens in a new window)
Targeted mass spectrometry-based assays enable multiplex quantification of receptor tyrosine kinase, MAP Kinase, and AKT signaling. Whiteaker JR, Sharma K, Hoffman MA, Kuhn E, Zhao L, Cocco AR, Schoenherr RM, Kennedy JJ, Voytovich U, Lin C, Fang B, Bowers K, Whiteley G, Colantonio S, Bocik W, Roberts R, Hiltke T, Boja E, Rodriguez H, McCormick F, Holderfield M, Carr SA, Koomen JM, Paulovich AG. Cell Reports Methods doi: 10.1016/j.crmeth.2021.100015.
Data source: Panorama
Broad Institute-Biologist curated set of targets across a number of important cancer pathways
Data source: Panorama
Data source: Panorama
Retrieving Data
Data source: Panorama
| Average intra-assay CV (within day CV) |
Average inter-assay CV (between day CV) |
Total CV |
n= | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Fragment ion / Transition | Low | Med | High | Low | Med | High | Low | Med | High | Low | Med | High |
| y5 (1+) | 20.9 | 12.8 | 7.1 | 28.5 | 23.3 | 11.4 | 35.3 | 26.6 | 13.4 | 16 | 15 | 17 |
| y6 (1+) | 19.9 | 9.6 | 11.2 | 19.6 | 17.4 | 17.5 | 27.9 | 19.9 | 20.8 | 16 | 15 | 17 |
| y7 (1+) | 25 | 12.4 | 15.9 | 31.6 | 21.8 | 22.5 | 40.3 | 25.1 | 27.6 | 16 | 15 | 17 |
| sum | 21.3 | 12.8 | 7.1 | 28.8 | 23.7 | 11.9 | 35.8 | 26.9 | 13.9 | 16 | 15 | 17 |
Data source: Panorama
View Details (opens in a new window)
Targeted mass spectrometry-based assays enable multiplex quantification of receptor tyrosine kinase, MAP Kinase, and AKT signaling. Whiteaker JR, Sharma K, Hoffman MA, Kuhn E, Zhao L, Cocco AR, Schoenherr RM, Kennedy JJ, Voytovich U, Lin C, Fang B, Bowers K, Whiteley G, Colantonio S, Bocik W, Roberts R, Hiltke T, Boja E, Rodriguez H, McCormick F, Holderfield M, Carr SA, Koomen JM, Paulovich AG. Cell Reports Methods doi: 10.1016/j.crmeth.2021.100015.
Data source: Panorama
Broad Institute-Biologist curated set of targets across a number of important cancer pathways
Data source: Panorama
Data source: Panorama
Retrieving Data
Data source: Panorama
| Average intra-assay CV (within day CV) |
Average inter-assay CV (between day CV) |
Total CV |
n= | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Fragment ion / Transition | Low | Med | High | Low | Med | High | Low | Med | High | Low | Med | High |
| y5 (1+) | 6.8 | 7.3 | 5.3 | 11.2 | 12.4 | 12.8 | 13.1 | 14.4 | 13.9 | 16 | 15 | 16 |
| y15 (2+) | 6 | 7.5 | 4.6 | 9.8 | 13.2 | 10.9 | 11.5 | 15.2 | 11.8 | 16 | 15 | 16 |
| sum | 6.6 | 7.3 | 4.7 | 10.9 | 12.5 | 12.1 | 12.7 | 14.5 | 13 | 16 | 15 | 16 |
Data source: Panorama
View Details (opens in a new window)
Targeted mass spectrometry-based assays enable multiplex quantification of receptor tyrosine kinase, MAP Kinase, and AKT signaling. Whiteaker JR, Sharma K, Hoffman MA, Kuhn E, Zhao L, Cocco AR, Schoenherr RM, Kennedy JJ, Voytovich U, Lin C, Fang B, Bowers K, Whiteley G, Colantonio S, Bocik W, Roberts R, Hiltke T, Boja E, Rodriguez H, McCormick F, Holderfield M, Carr SA, Koomen JM, Paulovich AG. Cell Reports Methods doi: 10.1016/j.crmeth.2021.100015.
Data source: Panorama
Broad Institute-Biologist curated set of targets across a number of important cancer pathways
Data source: Panorama
Data source: Panorama
Retrieving Data
Data source: Panorama
| Average intra-assay CV (within day CV) |
Average inter-assay CV (between day CV) |
Total CV |
n= | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Fragment ion / Transition | Low | Med | High | Low | Med | High | Low | Med | High | Low | Med | High |
| y8 (1+) | 22.3 | 12.4 | 11.8 | 25.4 | 32.1 | 16.3 | 33.8 | 34.4 | 20.1 | 15 | 15 | 15 |
| y10 (1+) | 29.9 | 8.6 | 11.5 | 25.4 | 33.2 | 16.3 | 39.2 | 34.3 | 19.9 | 15 | 15 | 15 |
| sum | 23.9 | 11.4 | 11.7 | 25.1 | 32.2 | 16.3 | 34.7 | 34.2 | 20.1 | 15 | 15 | 15 |
Data source: Panorama
View Details (opens in a new window)
Targeted mass spectrometry-based assays enable multiplex quantification of receptor tyrosine kinase, MAP Kinase, and AKT signaling. Whiteaker JR, Sharma K, Hoffman MA, Kuhn E, Zhao L, Cocco AR, Schoenherr RM, Kennedy JJ, Voytovich U, Lin C, Fang B, Bowers K, Whiteley G, Colantonio S, Bocik W, Roberts R, Hiltke T, Boja E, Rodriguez H, McCormick F, Holderfield M, Carr SA, Koomen JM, Paulovich AG. Cell Reports Methods doi: 10.1016/j.crmeth.2021.100015.
Data source: Panorama
Broad Institute-Biologist curated set of targets across a number of important cancer pathways
Data source: Panorama
Data source: Panorama
Retrieving Data
Data source: Panorama
| Average intra-assay CV (within day CV) |
Average inter-assay CV (between day CV) |
Total CV |
n= | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Fragment ion / Transition | Low | Med | High | Low | Med | High | Low | Med | High | Low | Med | High |
| y8 (1+) | 63.6 | 50 | 13.2 | 50.8 | 36.7 | 31.4 | 81.4 | 62 | 34.1 | 15 | 15 | 15 |
| y10 (1+) | 58.5 | 40.9 | 11.7 | 55.2 | 40.4 | 23.2 | 80.4 | 57.5 | 26 | 15 | 15 | 15 |
| y11 (1+) | 80.8 | 51.1 | 15.2 | 58.5 | 32.6 | 27.2 | 99.8 | 60.6 | 31.2 | 15 | 15 | 15 |
| sum | 66.5 | 45.1 | 7.9 | 51.4 | 33.9 | 25.4 | 84 | 56.4 | 26.6 | 15 | 15 | 15 |
Data source: Panorama
View Details (opens in a new window)
Targeted mass spectrometry-based assays enable multiplex quantification of receptor tyrosine kinase, MAP Kinase, and AKT signaling. Whiteaker JR, Sharma K, Hoffman MA, Kuhn E, Zhao L, Cocco AR, Schoenherr RM, Kennedy JJ, Voytovich U, Lin C, Fang B, Bowers K, Whiteley G, Colantonio S, Bocik W, Roberts R, Hiltke T, Boja E, Rodriguez H, McCormick F, Holderfield M, Carr SA, Koomen JM, Paulovich AG. Cell Reports Methods doi: 10.1016/j.crmeth.2021.100015.
Data source: Panorama
Broad Institute-Biologist curated set of targets across a number of important cancer pathways
Data source: Panorama
Data source: Panorama
Retrieving Data
Data source: Panorama
| Average intra-assay CV (within day CV) |
Average inter-assay CV (between day CV) |
Total CV |
n= | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Fragment ion / Transition | Low | Med | High | Low | Med | High | Low | Med | High | Low | Med | High |
| y7 (1+) | 13.4 | 5.2 | 4.1 | 15.1 | 5 | 6.2 | 20.2 | 7.2 | 7.4 | 15 | 15 | 15 |
| y8 (1+) | 4.2 | 1.6 | 2.8 | 5.4 | 2.7 | 3.2 | 6.8 | 3.1 | 4.3 | 15 | 15 | 15 |
| b3 (1+) | 6 | 2.7 | 2.2 | 7.1 | 3 | 3.3 | 9.3 | 4 | 4 | 15 | 15 | 15 |
| y6 (1+) | 7.2 | 4 | 3.8 | 7 | 4 | 4.1 | 10 | 5.7 | 5.6 | 15 | 15 | 15 |
| sum | 3.3 | 1.4 | 2 | 4.8 | 2.3 | 2.7 | 5.8 | 2.7 | 3.4 | 15 | 15 | 15 |
Data source: Panorama
View Details (opens in a new window)
Targeted mass spectrometry-based assays enable multiplex quantification of receptor tyrosine kinase, MAP Kinase, and AKT signaling. Whiteaker JR, Sharma K, Hoffman MA, Kuhn E, Zhao L, Cocco AR, Schoenherr RM, Kennedy JJ, Voytovich U, Lin C, Fang B, Bowers K, Whiteley G, Colantonio S, Bocik W, Roberts R, Hiltke T, Boja E, Rodriguez H, McCormick F, Holderfield M, Carr SA, Koomen JM, Paulovich AG. Cell Reports Methods doi: 10.1016/j.crmeth.2021.100015.
Data source: Panorama
Broad Institute-Biologist curated set of targets across a number of important cancer pathways
Data source: Panorama
Data source: Panorama
Retrieving Data
Data source: Panorama
| Average intra-assay CV (within day CV) |
Average inter-assay CV (between day CV) |
Total CV |
n= | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Fragment ion / Transition | Low | Med | High | Low | Med | High | Low | Med | High | Low | Med | High |
| b2 (1+) | 19 | 6.4 | 5 | 27.6 | 30 | 15.6 | 33.5 | 30.7 | 16.4 | 14 | 14 | 14 |
| y5 (1+) | 22.3 | 6.1 | 5.7 | 26.1 | 27 | 15.3 | 34.3 | 27.7 | 16.3 | 14 | 14 | 14 |
| y6 (1+) | 19.3 | 7.9 | 4.9 | 26 | 31 | 17 | 32.4 | 32 | 17.7 | 14 | 14 | 14 |
| y7 (1+) | 19 | 6.1 | 4.4 | 26.7 | 30.2 | 15.9 | 32.8 | 30.8 | 16.5 | 14 | 14 | 14 |
| sum | 18.6 | 6.2 | 4.7 | 25.6 | 29.8 | 15.9 | 31.6 | 30.4 | 16.6 | 14 | 14 | 14 |
Data source: Panorama
View Details (opens in a new window)
Targeted mass spectrometry-based assays enable multiplex quantification of receptor tyrosine kinase, MAP Kinase, and AKT signaling. Whiteaker JR, Sharma K, Hoffman MA, Kuhn E, Zhao L, Cocco AR, Schoenherr RM, Kennedy JJ, Voytovich U, Lin C, Fang B, Bowers K, Whiteley G, Colantonio S, Bocik W, Roberts R, Hiltke T, Boja E, Rodriguez H, McCormick F, Holderfield M, Carr SA, Koomen JM, Paulovich AG. Cell Reports Methods doi: 10.1016/j.crmeth.2021.100015.
Data source: Panorama
Broad Institute-Biologist curated set of targets across a number of important cancer pathways
Data source: Panorama
Data source: Panorama
Retrieving Data
Data source: Panorama
| Average intra-assay CV (within day CV) |
Average inter-assay CV (between day CV) |
Total CV |
n= | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Fragment ion / Transition | Low | Med | High | Low | Med | High | Low | Med | High | Low | Med | High |
| y15 (2+) | 7.7 | 3.4 | 2.7 | 8.4 | 4.8 | 2.8 | 11.4 | 5.9 | 3.9 | 15 | 15 | 15 |
| y17 (2+) | 6 | 2.5 | 2.7 | 7.6 | 4.9 | 4.4 | 9.7 | 5.5 | 5.2 | 15 | 15 | 15 |
| y5 (1+) | 3.7 | 1.6 | 2.2 | 3.7 | 2.9 | 3.2 | 5.2 | 3.3 | 3.9 | 15 | 15 | 15 |
| y9 (1+) | 9.9 | 5 | 3.1 | 10.7 | 5.7 | 4.1 | 14.6 | 7.6 | 5.1 | 15 | 15 | 15 |
| sum | 3.2 | 1.1 | 1.6 | 3.6 | 3.1 | 2.8 | 4.8 | 3.3 | 3.2 | 15 | 15 | 15 |
Data source: Panorama
View Details (opens in a new window)
Targeted mass spectrometry-based assays enable multiplex quantification of receptor tyrosine kinase, MAP Kinase, and AKT signaling. Whiteaker JR, Sharma K, Hoffman MA, Kuhn E, Zhao L, Cocco AR, Schoenherr RM, Kennedy JJ, Voytovich U, Lin C, Fang B, Bowers K, Whiteley G, Colantonio S, Bocik W, Roberts R, Hiltke T, Boja E, Rodriguez H, McCormick F, Holderfield M, Carr SA, Koomen JM, Paulovich AG. Cell Reports Methods doi: 10.1016/j.crmeth.2021.100015.
Data source: Panorama
Broad Institute-Biologist curated set of targets across a number of important cancer pathways
Data source: Panorama
Data source: Panorama
Retrieving Data
Data source: Panorama
| Average intra-assay CV (within day CV) |
Average inter-assay CV (between day CV) |
Total CV |
n= | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Fragment ion / Transition | Low | Med | High | Low | Med | High | Low | Med | High | Low | Med | High |
| y5 (1+) | 1.8 | 1 | 1.1 | 2.5 | 1.3 | 1.9 | 3.1 | 1.6 | 2.2 | 15 | 15 | 15 |
| y6 (1+) | 3.4 | 3.5 | 3.2 | 6.7 | 3.2 | 2.9 | 7.5 | 4.7 | 4.3 | 15 | 15 | 15 |
| y9 (1+) | 4.5 | 2.8 | 2.5 | 4.6 | 3.3 | 3 | 6.4 | 4.3 | 3.9 | 15 | 15 | 15 |
| y5 (2+) | 3.6 | 2.5 | 1.1 | 4.6 | 2.3 | 1.9 | 5.8 | 3.4 | 2.2 | 15 | 15 | 15 |
| y15 (2+) | 4.4 | 3.8 | 2.7 | 4.5 | 4.2 | 2.6 | 6.3 | 5.7 | 3.7 | 15 | 15 | 15 |
| sum | 1.3 | 0.5 | 0.7 | 2.3 | 0.6 | 1.2 | 2.6 | 0.8 | 1.4 | 15 | 15 | 15 |
Data source: Panorama
View Details (opens in a new window)
Targeted mass spectrometry-based assays enable multiplex quantification of receptor tyrosine kinase, MAP Kinase, and AKT signaling. Whiteaker JR, Sharma K, Hoffman MA, Kuhn E, Zhao L, Cocco AR, Schoenherr RM, Kennedy JJ, Voytovich U, Lin C, Fang B, Bowers K, Whiteley G, Colantonio S, Bocik W, Roberts R, Hiltke T, Boja E, Rodriguez H, McCormick F, Holderfield M, Carr SA, Koomen JM, Paulovich AG. Cell Reports Methods doi: 10.1016/j.crmeth.2021.100015.
Data source: Panorama
Broad Institute-Biologist curated set of targets across a number of important cancer pathways
Data source: Panorama
Data source: Panorama
Retrieving Data
Data source: Panorama
| Average intra-assay CV (within day CV) |
Average inter-assay CV (between day CV) |
Total CV |
n= | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Fragment ion / Transition | Low | Med | High | Low | Med | High | Low | Med | High | Low | Med | High |
| y6 (1+) | 18.7 | 10.1 | 12 | 24.3 | 33.5 | 15.6 | 30.7 | 35 | 19.7 | 14 | 14 | 14 |
| y8 (1+) | 20.5 | 9.5 | 12.4 | 27.6 | 33.3 | 15.6 | 34.4 | 34.6 | 19.9 | 14 | 14 | 14 |
| y10 (1+) | 27.6 | 8.6 | 11.9 | 27.8 | 35.2 | 15.8 | 39.2 | 36.2 | 19.8 | 14 | 14 | 14 |
| y11 (1+) | 29 | 13.1 | 10.3 | 33.2 | 32.6 | 15.7 | 44.1 | 35.1 | 18.8 | 14 | 14 | 14 |
| sum | 21.3 | 9.5 | 12 | 27 | 33.6 | 15.6 | 34.4 | 34.9 | 19.7 | 14 | 14 | 14 |
Data source: Panorama
Data source: Panorama
Broad Institute-Biologist curated set of targets across a number of important cancer pathways
Data source: Panorama
Data source: Panorama
Retrieving Data
Data source: Panorama
| Average intra-assay CV (within day CV) |
Average inter-assay CV (between day CV) |
Total CV |
n= | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Fragment ion / Transition | Low | Med | High | Low | Med | High | Low | Med | High | Low | Med | High |
| y3 (1+) | 26.8 | 4.6 | 3.5 | 35.6 | 6.7 | 3.8 | 44.6 | 8.1 | 5.2 | 15 | 15 | 15 |
| y5 (1+) | 6.6 | 4.5 | 1.8 | 6.7 | 4.8 | 1.9 | 9.4 | 6.6 | 2.6 | 15 | 15 | 15 |
| y6 (1+) | 19.8 | 14.5 | 1.6 | 24.6 | 18.7 | 5.7 | 31.6 | 23.7 | 5.9 | 15 | 15 | 15 |
| sum | 6.5 | 2.8 | 1.2 | 7.3 | 4.7 | 2.1 | 9.8 | 5.5 | 2.4 | 15 | 15 | 15 |
Data source: Panorama
Data source: Panorama
Broad Institute-Biologist curated set of targets across a number of important cancer pathways
Data source: Panorama
Data source: Panorama
Retrieving Data
Data source: Panorama
| Average intra-assay CV (within day CV) |
Average inter-assay CV (between day CV) |
Total CV |
n= | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Fragment ion / Transition | Low | Med | High | Low | Med | High | Low | Med | High | Low | Med | High |
| y7 (1+) | 11.9 | 3.4 | 2.4 | 15.2 | 4.8 | 6.6 | 19.3 | 5.9 | 7 | 15 | 15 | 15 |
| y5 (1+) | 39 | 6.4 | 5 | 55.8 | 7.6 | 8.2 | 68.1 | 9.9 | 9.6 | 15 | 15 | 15 |
| y3 (1+) | 29.2 | 5.2 | 6.5 | 21.8 | 4.3 | 9.8 | 36.4 | 6.7 | 11.8 | 15 | 15 | 15 |
| b2 (1+) | 9.7 | 3.5 | 3.1 | 10.6 | 5.6 | 6.4 | 14.4 | 6.6 | 7.1 | 15 | 15 | 15 |
| sum | 6 | 2.8 | 2.1 | 10.4 | 4.7 | 6.2 | 12 | 5.5 | 6.5 | 15 | 15 | 15 |
Comments